Skip to main content
. 2021 Dec 16;9:785796. doi: 10.3389/fcell.2021.785796

FIGURE 5.

FIGURE 5

Molecular mechanism studies in HER2+/HR+ breast cancer cell lines after treatment and in vivo anticancer effect of PYR and SHR in cancer xenograft models. EFM-192A cells were treated with PBS, PBS (CON), PYR (0.16, 0.4 μg/ml), SHR (0.6, 1.5 μg/ml) or PYR (0.4 μg/ml), and SHR (1.5 μg/ml) for 24 h, respectively. BT474 cells were treated with PBS, PYR (0.96, 2.4 μg/ml), SHR (1.2, 3 μg/ml) or PYR (2.4 μg/ml), and SHR (3 μg/ml) for 24 h, respectively. Nuclear and cytosolic protein extracts were subjected to Western blot analysis. (5A,5B) The results of Western blot for FOXM1, pFOXM1, NFκB, pNFκB, GSK3β, pGSK3β, RB, and pRB in the nuclear fractions and cytosolic extracts, respectively. GAPDH served as the loading control. (5C,5D) Quantitative analysis of the Western blotting results. Data represent the mean ±S.D. of three independent experiments. Randomly grouped nude mice were treated with PBS (Vehicle), PYR (10 mg/kg/day), SHR (75 mg/kg/day), or a combination treatment (PYR+SHR) for 25 days. (5E) Photos of the excised tumors. (5F,5G) Tumor growth ratio curve and body weight changes every 3 days after the onset of treatment. (5H) Weight obtained on day 25 after treatment, *p < 0.05, **p < 0.01, ***p < 0.001 compared with the control.